Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC)
Latest Information Update: 27 Sep 2024
At a glance
- Drugs Atezolizumab (Primary) ; Tiragolumab (Primary) ; Carboplatin; Cisplatin
- Indications Mouth neoplasm; Squamous cell cancer
- Focus Therapeutic Use
- 19 Sep 2024 Planned primary completion date changed from 1 Nov 2024 to 1 Nov 2025.
- 06 Jun 2023 Status changed from not yet recruiting to recruiting.
- 13 Jan 2023 New trial record